F-1: Biodexa Pharmaceuticals Seeks to Resell 2.49 Billion Ordinary Shares via Prospectus

Biodexa Pharmaceuticals is registering for resale up to 2,486,270,400 ordinary shares represented by 6,215,676 American Depositary Shares by selling shareholders.

Summary

• Biodexa Pharmaceuticals has filed a Form F-1 registration statement for the resale of up to 2,486,270,400 ordinary shares, represented by 6,215,676 American Depositary Shares (ADSs), by selling shareholders.
• These shares are issuable upon the exercise of warrants from a May 2024 private placement and warrant agent warrants.
• The selling shareholders may sell these shares from time to time in market transactions.
• Biodexa will not receive any proceeds from the sale of ADSs by the selling shareholders, but may receive proceeds from the exercise of warrants.
• The company's ADSs are listed on the NASDAQ Capital Market under the symbol BDRX, and the last reported closing price on June 5, 2024, was $0.99.
• The document highlights recent developments including a warrant inducement on May 22, 2024, and a license and collaboration agreement with Emtora Biosciences on April 25, 2024, for eRapa, a rapamycin formulation.
• The company issued 378,163 Depositary Shares to Emtora as part of the licensing agreement.
• The company is developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, including familial adenomatous polyposis, or FAP, non-muscle invasive bladder cancer, or NMIBC, type 1 diabetes, or T1D, and rare/orphan cancers of the brain.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document primarily concerns the registration of shares for resale, with both positive aspects (potential for capital from warrant exercises) and negative aspects (potential dilution and price pressure).

Positives

• The license and collaboration agreement with Emtora Biosciences provides Biodexa with an exclusive, worldwide, sublicensable right to develop, manufacture, and commercialize products containing rapamycin.
• The warrant inducement generated gross proceeds of approximately $6.05 million for the company.
• The company has a pipeline of innovative products for the treatment of diseases with unmet medical needs, including familial adenomatous polyposis, or FAP, non-muscle invasive bladder cancer, or NMIBC, type 1 diabetes, or T1D, and rare/orphan cancers of the brain.

Negatives

• The company will not receive any proceeds from the sale of ADSs by the selling shareholders, only from potential warrant exercises.
• The company is registering for resale 2,486,270,400 ordinary shares represented by 6,215,676 ADSs held by selling shareholders, including shares issuable upon the exercise of warrants held by the selling shareholders, which could adversely affect the prevailing market price of the company's Ordinary Shares and/or Depositary Shares.
• The company may issue additional Ordinary Shares (including Ordinary Shares represented by Depositary Shares) in the future, which could result in substantial dilution to the company's existing shareholders and could cause the company's share price to decline.

Risks

• The sale of a substantial amount of Ordinary Shares (represented by Depositary Shares), including resale of the Ordinary Shares (represented by Depositary Shares) issuable upon the exercise of the warrants held by the selling shareholders in the public market, could adversely affect the prevailing market price of the company's Ordinary Shares and/or Depositary Shares.
• The company may issue additional Ordinary Shares (including Ordinary Shares represented by Depositary Shares) in the future, which could result in substantial dilution to the company's existing shareholders and could cause the company's share price to decline.

Future Outlook

An ongoing Phase 2 study of eRapa in NMIBC is scheduled to report results in mid-2025.

Industry Context

The announcement reflects a common practice in the biopharmaceutical industry where companies raise capital through private placements and then register the shares for resale to provide liquidity to investors.

Stakeholder Impact

• Existing shareholders may experience dilution if warrants are exercised and new shares are issued.
• Selling shareholders will gain liquidity through the resale of their shares.
• The company may benefit from potential proceeds if warrants are exercised for cash.

Next Steps

• Selling shareholders may sell their Ordinary Shares represented by Depositary Shares as described under Plan of Distribution.
• The company will receive the proceeds from any exercise of the warrants exercised for cash.

Key Dates

Keywords

Depositary Shares, Ordinary Shares, Warrants, eRapa, Rapamycin, Biodexa Pharmaceuticals, Resale, Selling Shareholders, Private Placement, License Agreement